Sun Pharmaceutical Industries Ltd announced an exclusive licensing, commercialisation and manufacturing agreement with LIB Therapeutics Inc for lerodalcibep, a PCSK9 inhibitor, across markets outside the United States and China.

Sun Pharmaceutical Industries Ltd announced an exclusive licensing, commercialisation and manufacturing agreement with LIB Therapeutics Inc for lerodalcibep, a PCSK9 inhibitor, across markets outside the United States and China.

Sun Pharmaceutical Industries has entered into an exclusive agreement with US-based LIB Therapeutics to manufacture, commercialise, and globally license lerodalcibep in all markets outside the United States and China.

Sun Pharmaceutical Industries has entered into an exclusive licensing agreement with LIB Therapeutics to commercialize and manufacture lerodalcibep, a PCSK9 inhibitor used to lower LDL cholesterol, across global markets outside the US and China.

Sun Pharmaceutical Industries and LIB Therapeutics Inc. announced an exclusive licensing agreement granting Sun Pharma rights to commercialize and manufacture lerodalcibep worldwide, excluding the United States and China.

Sun Pharmaceutical Industries has signed a global licensing deal with US-based LIB Therapeutics for Lerodalcibep, a once-monthly drug used to lower bad cholesterol, giving it exclusive rights to commercialise and manufacture the medicine outside the US and China.

Sun Pharma has entered into an exclusive licensing agreement with LIB Therapeutics Inc. for the commercialization and manufacture of lerodalcibep worldwide, excluding the US and China.